It comprises the CD56-binding antibody, lorvotuzumab (huN901), with a maytansinoid cell-killing agent, DM1, attached using a disulfide linker, SPP.

(When DM1 is attached to an antibody with the SPP linker, it is mertansine; when it is attached with the thioether linker, SMCC, it is emtansine.

[1][2] It has been granted Orphan drug status for Merkel cell carcinoma.

[3] It has reported encouraging Phase II results for small-cell lung cancer.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.